An interventional study of Respiratory physiotherapy and Conservative Treatment in Rib Fractures and Spirometry, sponsored by Kastamonu University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Kastamonu University · Not applicable, Interventional, and Supportive care
Among 13 studies in Rib Fractures with a site in Turkey — 3 open to participants now, 4 under way, none of them phase 3. Rib Fractures · Turkey.
Among the 13 studies in Rib Fractures with a site in Turkey, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2024, is one of 8 with no phase, and was the 4th registered.
126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.
This study's planned enrollment of 62 is close to the median of 60 across 92 interventional studies indexed under Rib Fractures.
Browse Rib Fractures studies →3 of the 13 studies in Rib Fractures with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 13 Rib Fractures studies recruiting now, 9 (69%) set no upper age limit and 1 (8%) stop at 75 or younger; 0 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →13 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2024.
Median enrollment 61 across the 12 interventional studies, 151 across the 1 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
None of the 13 has an industry lead sponsor. The 8 most frequent:
Kastamonu University is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Kastamonu University has 2 studies filed under Rib Fractures — fewer than ten, so there is no comparison to draw.
1 of the studies in Rib Fractures with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07238582Caner İşevi, MDEffectiveness of an Innovative Chest Stabilizer in Rib Fracture Treatment: Impact on Respiratory Function, Complications, and Clinical Outcomes | 2027-09-01 |
Among the 13 studies in Rib Fractures with a site in Turkey, from their registry updates:
Respiratory physiotherapy is routinely performed after thoracic surgery operations to increase lung expansion and prevent pulmonary complications such as atelectasis and pneumonia. It is a controversial issue whether respiratory physiotherapy reduces pulmonary complications in rib fractures. In our study, patients with rib fractures will be divided into two groups. In the control group, standard treatment consisting of routine analgesic treatments will be applied. In the other group, respiratory physiotherapy will be applied with triflu for 8 hours a day. At the end of the study, pulmonary complications in both groups will be compared.
Patients between the ages of 18 and 100 who will apply to our hospital due to rib fractures between April 2024 and April 2025 will be evaluated. Patients who meet the inclusion criteria will be included in the study. Patients will be divided into two groups using randomization blocks. Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen. In the other group of patients, in addition to conservative treatment, triflow breathing exercise will be applied for 8 hours a day. Respiratory function test pain scores and pulmonary complications of patients in the two groups will be compared statistically.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour
Behavioral: Respiratory physiotherapy
Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
Drug: Conservative Treatment
In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
Also known as: Triflow
Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
Also known as: Control
FEV1, FVC, FEV1/FVC results on day 7
FEV1, FVC, FEV1/FVC
Time frame: 7 days
Number of Participants with Pneumonia
Clinical and radiological diagnosis of pneumonia
Time frame: 7 days
FEV1, FVC, FEV1/FVC results on day 2
FEV1, FVC, FEV1/FVC
Time frame: 2 days
Plan to share: Yes — Yes
Time frame: Data will be available permanently on 1.4.2025
Access criteria: Upon reasonable request principal investigator will share date
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.
Of 40 non-industry interventional studies with no phase under Rib Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 4 months is below that.
Counting every sponsor, half of 40 studies reached it within 23 months; a quarter within 15 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kastamonu University